Target intelligence / Profile preview

Peritoneal membrane (PM) (PM)

Target
PM
Molecular classification
Other (Biological Membrane/Tissue Interface)
01

Overview

The peritoneal membrane acts as a biological semi-permeable barrier utilized in peritoneal dialysis to remove metabolic waste and excess fluid from the blood of patients with renal failure [StatPearls, 2023]. Transport across this membrane is governed by the 'three-pore model,' which includes large pores for proteins, small pores for solutes like urea and creatinine, and ultra-small pores (Aquaporin-1) for water transport [Rippe, 1996; Ni, 2006]. The efficiency of this process is determined by the membrane's surface area and permeability, which can be assessed clinically using the Peritoneal Equilibration Test (PET) [Twardowski, 1987]. Chronic exposure to conventional dialysis solutions, particularly those with high glucose concentrations and glucose degradation products, can lead to structural changes such as mesothelial cell loss and fibrosis [Morelle, 2015]. These changes often result in ultrafiltration failure, a significant complication that may necessitate a transition to hemodialysis [Davies, 2001]. Therapeutic strategies focus on using biocompatible solutions to preserve the membrane's functional integrity over time [Cho, 2014].

Other names
Peritoneal barrierPeritoneal dialysis interfacePeritoneal surfacePeritoneal transport system
02

Mechanism of action

Facilitation of passive diffusion and osmotic ultrafiltration across a semi-permeable biological barrier to remove uremic toxins and excess fluid [StatPearls, 2023].

03

Biological functions

OsmosisDiffusionUltrafiltrationSolute transportFluid homeostasisOther (Biological filtration)
04

Disease associations

End-stage renal disease (ESRD)PeritonitisPeritoneal fibrosisEncapsulating peritoneal sclerosis (EPS)Other (Ultrafiltration failure)
05

Safety considerations

Ultrafiltration failurePeritoneal membrane fibrosisEncapsulating peritoneal sclerosisPeritonitisGlucose-induced metabolic complications (e.g., hyperglycemia, weight gain)
06

Interacting drugs

Dextrose

4 more in the full profile.

07

Biomarkers

D/P Creatinine ratioNet ultrafiltration volume (nUF)Kt/V ureaCancer Antigen 125 (CA125) in effluentGlucose absorption rate

Beyond the preview

Go deeper on Peritoneal membrane (PM) (PM).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Peritoneal membrane (PM) (PM).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call